FDA, Drug Development and Health Care Reform: A Panel Discussion
This article was originally published in RPM Report
Executive Summary
Current and former FDA officials and a former Big Pharma head of R&D discuss FDA and the relationship between a regulator and the industry it regulates when it comes to drug development.
You may also be interested in...
FDA and Cancer Drug Development: An Advocate's View
Friends of Cancer Research (www.focr.org) has been among the most vocal supporters of a robust FDA review process for oncology drugs. Chair & Founder Dr. Ellen Sigal has taken the advocacy group from a one-person shop to an organization with strong ties to the agency and the lawmakers on Capitol Hill who matter most to the future of cancer treatment.
FDA Drug Safety Update: Key Takeaways From IoM Workshop
It has been three years since an Institute of Medicine report on FDA's drug safety system, and two years since the landmark FDA Amendments Act that followed. As those anniversaries approached, IoM convened a workshop for an update on the changes at FDA since FDAAA. Here's what we heard.
FDAAA Impact Analysis: Year One
The RPM Report’s analysis of the fi rst year under FDA’s new law makes one fact clear: sponsors seeking approval for never-before-marketed ingredients need to assume the new tools will apply to them.